These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 26728706)

  • 1. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Huhn GD; Sigman A; Livak B
    Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
    La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
    Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
    Ghosn J; Slama L; Chermak A; Houssaini A; Lambert-Niclot S; Schneider L; Fourn E; Duvivier C; Simon A; Courbon E; Murphy R; Flandre P; Peytavin G; Katlama C;
    J Med Virol; 2013 Jan; 85(1):8-15. PubMed ID: 23024008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
    Ahmed N; Okoli C; Ainsworth J
    Int J STD AIDS; 2016 Mar; 27(4):321-2. PubMed ID: 25969439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
    Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C
    AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
    Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
    Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
    Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
    HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
    Burgos J; Crespo M; Falcó V; Curran A; Navarro J; Imaz A; Domingo P; Podzamczer D; Mateo MG; Villar S; Van den Eynde E; Ribera E; Pahissa A
    J Antimicrob Chemother; 2012 Oct; 67(10):2479-86. PubMed ID: 22729925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
    Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
    Taiwo B; Murphy RL; Katlama C
    Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
    Quercia R; Roberts J; Martin-Carpenter L; Zala C
    Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
    Lennox JL; Landovitz RJ; Ribaudo HJ; Ofotokun I; Na LH; Godfrey C; Kuritzkes DR; Sagar M; Brown TT; Cohn SE; McComsey GA; Aweeka F; Fichtenbaum CJ; Presti RM; Koletar SL; Haas DW; Patterson KB; Benson CA; Baugh BP; Leavitt RY; Rooney JF; Seekins D; Currier JS;
    Ann Intern Med; 2014 Oct; 161(7):461-71. PubMed ID: 25285539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
    Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
    HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
    Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
    Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
    Hakim JG; Thompson J; Kityo C; Hoppe A; Kambugu A; van Oosterhout JJ; Lugemwa A; Siika A; Mwebaze R; Mweemba A; Abongomera G; Thomason MJ; Easterbrook P; Mugyenyi P; Walker AS; Paton NI;
    Lancet Infect Dis; 2018 Jan; 18(1):47-57. PubMed ID: 29108797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.